Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D., Issaragrisil, S., le Coutre, P., . . . Hochhaus, A. (2021). Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia.
Styl ChicagoKantarjian, Hagop M., et al. "Long-term Outcomes With Frontline Nilotinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 10-year Analysis." Leukemia 2021.
Citace podle MLAKantarjian, Hagop M., et al. "Long-term Outcomes With Frontline Nilotinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 10-year Analysis." Leukemia 2021.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..